Danko Jeremic

Mr. Danko Jeremic

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ISIrene Sánchez-Rodríguez
Irene Sánchez-Rodríguez
STSara Temprano-Carazo
Sara Temprano-Carazo
DJDanko Jeremic
Danko Jeremic
JDJosé María Delgado-García
José María Delgado-García
AGAgnès Gruart
Agnès Gruart
LJLydia Jimenez-Diaz
Lydia Jimenez-Diaz
Synaptic plasticity is a cellular process involved in learning and memory by which specific patterns of neural activity adapt the synaptic strength and efficacy of the synaptic transmission. Its induction is governed by fine tuning between excitatory/inhibitory synaptic transmission. In experimental conditions, synaptic plasticity can be artificially evoked at hippocampal CA1 pyramidal neurons by repeated stimulation of Schaffer collaterals. However, long-lasting synaptic modifications studies during memory formation in physiological conditions in freely moving animals are very scarce. Here, to study synaptic plasticity phenomena during recognition memory in the dorsal hippocampus, field postsynaptic potentials (fPSPs) evoked at the CA3–CA1 synapse were recorded in freely moving mice during object-recognition task performance. Paired pulse stimuli were applied to Schaffer collaterals at the moment that the animal explored a new or a familiar object along different phases of the test. Stimulation evoked a complex synaptic response composed of an ionotropic excitatory glutamatergic fEPSP, followed by two inhibitory responses, an ionotropic, GABAA-mediated fIPSP and a metabotropic, G-protein-gated inwardly rectifying potassium (GirK) channel-mediated fIPSP. Our data showed the induction of LTP-like enhancements for both the glutamatergic and GirK-dependent components of the dorsal hippocampal CA3–CA1 synapse during the exploration of novel but not familiar objects. These results support the contention that synaptic plasticity processes that underlie hippocampal-dependent memory are sustained by fine tuning mechanisms that control excitatory and inhibitory neurotransmission balance.

20 July 2020 in Biology
Verified
Journal Article
Open access
PDF file
JMJennifer Mayordomo-Cava
Jennifer Mayordomo-Cava
GLGuillermo Iborra Lázaro
Guillermo Iborra Lázaro
SDSouhail Djebari
Souhail Djebari
STSara Temprano-Carazo
Sara Temprano-Carazo
ISIrene Sánchez-Rodríguez
Irene Sánchez-Rodríguez
JNJuan D. Navarro-Lopez
Juan D. Navarro-Lopez
In early Alzheimer disease (AD) models synaptic failures and upstreaming aberrant patterns of network synchronous activity result in hippocampal-dependent memory deficits. In such initial stage, soluble forms of Amyloid-β (Aβ) peptides have been shown to play a causal role. Among different Aβ species, Aβ25–35 has been identified as the biologically active fragment, as induces major neuropathological signs related to early AD stages. Consequently, it has been extensively used to acutely explore the pathophysiological events related with neuronal dysfunction induced by soluble Aβ forms. However, the synaptic mechanisms underlying its toxic effects on hippocampal-dependent memory remain unresolved. Here, in an in vivo model of amyloidosis generated by intracerebroventricular injections of Aβ25–35 we studied the synaptic dysfunction mechanisms underlying hippocampal cognitive deficits. At the synaptic level, long-term potentiation (LTP) of synaptic excitation and inhibition was induced in CA1 region by high frequency simulation (HFS) applied to Schaffer collaterals. Aβ25–35 was found to alter metaplastic mechanisms of plasticity, facilitating long-term depression (LTD) of both types of LTP. In addition, aberrant synchronization of hippocampal network activity was found while at the behavioral level, deficits in hippocampal-dependent habituation and recognition memories emerged. Together, our results provide a substrate for synaptic disruption mechanism underlying hippocampal cognitive deficits present in Aβ25–35 amyloidosis model.

16 September 2023 in Biology of Sex Differences
Verified
Journal Article
Open access
PDF file
RJRaquel Jiménez-Herrera
Raquel Jiménez-Herrera
ACAna Contreras
Ana Contreras
SDSouhail Djebari
Souhail Djebari
JMJaime Mulero-Franco
Jaime Mulero-Franco
GIGuillermo Iborra-Lázaro
Guillermo Iborra-Lázaro
LJLydia Jimenez-Diaz
Lydia Jimenez-Diaz
Background: The amyloid-β (Aβ) cascade is one of the most studied theories linked to AD. In multiple models, Aβ accumulation and dyshomeostasis have shown a key role in AD onset, leading to excitatory/inhibitory imbalance, the impairments of synaptic plasticity and oscillatory activity, and memory deficits. Despite the higher prevalence of Alzheimer’s disease (AD) in women compared to men, the possible sex difference is scarcely explored and the information from amyloidosis transgenic mice models is contradictory. Thus, given the lack of data regarding the early stages of amyloidosis in female mice, the aim of this study was to systematically characterize the effect of an intracerebroventricular (icv.) injection of Aβ1–42 on hippocampal-dependent memory, and on associated activity-dependent synaptic plasticity in the hippocampal CA1–CA3 synapse, in both male and female mice. Methods: To do so, we evaluated long term potentiation (LTP) with ex vivo electrophysiological recordings as well as encoding and retrieval of spatial (working, short- and long-term) and exploratory habituation memories using Barnes maze and object location, or open field habituation tasks, respectively. Results: Aβ1–42 administration impaired all forms of memory evaluated in this work, regardless of sex. This effect was displayed in a long-lasting manner (up to 17 days post-injection). LTP was inhibited at a postsynaptic level, both in males and females, and a long-term depression (LTD) was induced for the same prolonged period, which could underlie memory deficits. Conclusions: In conclusion, our results provide further evidence on the shifting of LTP/LTD threshold due to a single icv. Aβ1–42 injection, which underly cognitive deficits in the early stages of AD. These long-lasting cognitive and functional alterations in males and females validate this model for the study of early amyloidosis in both sexes, thus offering a solid alternative to the inconsistence of amyloidosis transgenic mice models.

7 April 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
DJDanko Jeremic
Danko Jeremic
JNJuan D. Navarro-Lopez
Juan D. Navarro-Lopez
LJLydia Jimenez-Diaz
Lydia Jimenez-Diaz
Background: Despite the increasing approval of antiamyloid antibodies for Alzheimer disease (AD), their clinical relevance and risk-benefit profile remain uncertain. The heterogeneity of AD and the limited availability of long-term clinical data make it difficult to establish a clear rationale for selecting one treatment over another. Objective: The aim of this work was to assess and compare the efficacy and safety of antiamyloid antibodies through an interactive online meta-analytic approach by performing conventional pair-wise meta-analyses and frequentist and Bayesian network meta-analyses of phase II and III clinical trial results. To achieve this, we developed AlzMeta.app 2.0, a freely accessible web application that enables researchers and clinicians to evaluate the relative and absolute risks and benefits of these therapies in real time, incorporating different prior choices and assumptions of baseline risks of disease progression and adverse events. Methods: We adhered to PRISMA-NMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for reporting of systematic reviews with network meta-analysis) and GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) guidelines for reporting and rating the certainty of evidence. Clinical trial reports (until September 30, 2024) were retrieved from PubMed, Google Scholar, and clinical trial databases (including ClinicalTrials.gov). Studies with <20 sporadic AD patients and a modified Jadad score <3 were excluded. Risk of bias was assessed with the RoB-2 tool. Relative risks and benefits have been expressed as risk ratios and standardized mean differences, with confidence, credible, and prediction intervals calculated for all outcomes. For significant results, the intervention effects were ranked in frequentist and Bayesian frameworks, and their clinical relevance was determined by the absolute risk per 1000 people and number needed to treat (NNT) for a wide range of control responses. Results: Among 7 treatments tested in 21,236 patients (26 studies with low risk of bias or with some concerns), donanemab was the best-ranked treatment on cognitive and functional measures, and it was almost 2 times more effective than aducanumab and lecanemab and significantly more beneficial than other treatments on the global (cognitive and functional) Clinical Dementia Rating Scale-Sum of Boxes (NNT=10, 95% CI 8-16). Special caution is required regarding cerebral edema and microbleeding due to the clinically relevant risks of edema for donanemab (NNT=8, 95% CI 5-16), aducanumab (NNT=10, 95% CI 6-17), and lecanemab (NNT=14, 95% CI 7-31), which may outweigh the benefits. Conclusions: Our results showed that donanemab is more effective and has a safety profile similar to aducanumab and lecanemab, highlighting the need for treatment options with improved safety. Potential bias may have been introduced in the included trials due to unblinding caused by frequent cerebral edema and microbleeds, as well as the impact of the COVID-19 pandemic.

1 April 2024 in medRxiv
Verified
Preprint
Open access
PDF file
DJDanko Jeremic
Danko Jeremic
JNJuan D. Navarro-Lopez
Juan D. Navarro-Lopez
LJLydia Jimenez-Diaz
Lydia Jimenez-Diaz
INTRODUCTION: Questions remain regarding safety and clinical relevance of anti-amyloid antibodies in Alzheimer’s disease (AD), with no scientific basis for choosing between different therapies. METHODS: Systematic review, frequentist and Bayesian network meta-analyses of phase III randomized placebo-controlled trials were performed to comparatively evaluate cognitive, functional and biomarker efficacy and safety of anti-amyloid antibodies in sporadic AD. Treatments were ranked with P- and SUCRA scores, with rank robustness measured by Cohen’s kappa , and uncertainty in ranking probabilities estimated with Shannon’s normalized entropy. RESULTS: Based on data from 16,971 patients (16 studies), we found Donanemab the best-ranked antibody on cognitive measures. Lecanemab was the most effective at reducing amyloid burden. Caution is needed concerning brain edema and microbleeding, with clinically important risks for Donanemab, Aducanumab and Lecanemab. DISCUSSION: Risk/benefit profile of anti-amyloid antibodies remains unfavorable. Patients in Donanemab study were stratified by tau load, with greater effects observed in low/medium tau population. Highlights: No single therapy ranked the best among all outcomes. Donanemab was the most effective antibody at reducing cognitive decline across all primary outcomes, while Lecanemab ranked the highest on amyloid PET removal. Consistently greater cognitive, functional and biomarker effects of Donanemab were observed in patients with low/medium tau load, suggesting more promising effects in earlier AD stages. All antibodies, except Solanezumab, were significantly less tolerable than Placebo. The risk of cerebral edema and microbleeding may outweigh the benefits, independently of APOE status.

16 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
DJDanko Jeremic
Danko Jeremic
LJLydia Jimenez-Diaz
Lydia Jimenez-Diaz
JNJuan D. Navarro-Lopez
Juan D. Navarro-Lopez
G protein-gated inwardly rectifying potassium (GIRK) channels are key regulators of neuronal excitability, making them promising therapeutic targets for central nervous system disorders. Their activation depends on phosphatidylinositol-4,5-bisphosphate (PIP 2 ), which stabilizes the channel’s open state. A deeper understanding of GIRK-PIP 2 interactions could uncover new physiological roles and pave the way for therapies that modulate channel function. This study aimed to advance the targeting of GIRK channels at the PIP 2 -binding site. Over one million compounds were screened against GIRK2 (PDB ID: 4KFM) using high-throughput virtual screening. A core constraint with a root-mean-square deviation (RMSD) < 2 Å was applied to assure the accuracy and binding close to PIP 2 -binding site. The top-scoring ligands were redocked with Glide (SP, XP) and binding free energy was estimated using Molecular Mechanics Generalized Born Surface Area method. The most promising compounds were analyzed for pharmacokinetic/physicochemical properties, followed by molecular dynamics (MD) simulations over 200 ns in membrane bilayer. MD analysis revealed three known compounds (Rosuvastatin, CID: 54365126 and 7304563) as potential competitive GIRK2 modulators, exhibiting stable interactions with residues critical for binding endogenous activators (PIP 2 , cholesterol), and GIRK-acting drugs. Docking analyses also revealed strong binding to GIRK2 for various metabolites, including leukotrienes, resolvins, acyl-CoAs, and polyphosphates, including adenosine-triphosphate (ATP) and thiamine-triphosphate. Notably, some of the identified compounds can affect similar ion channels, indicating potential cross-reactivity with GIRK2. Furthermore, the binding modes of acyl-CoAs and polyphosphates closely resemble PIP 2 ’s hydrophobic and phosphate group engagement. Together, these findings offer promising candidates for experimental validation and therapeutic development. Graphical Abbreviations: ADMET – Absorption, Distribution, Metabolism, Elimination, Toxicity; CID – PubChem Compound Identification; MM-GBSA – Molecular Mechanics with Generalized Born and Surface Area solvation; RMSD - Root-Mean-Square Deviation; SP – Standard Precision; PIP 2 – phosphatidylinositol-4,5-bisphosphate; XP – Extra Precision. HIGHLIGHTS: Multi-target screening identifies selective modulators of the GIRK2 channel Ligands target the PIP2-binding site, a novel interface for GIRK2 modulation MM-GBSA confirms binding affinity and ligand stability post-docking Dynamics and bioinformatics predict selectivity and off-target interactions Statins and leukotriene-modifying drugs are strong GIRK2 modulator candidates